Therapeutic Effects of Lifei Decoction in a Murine Model of COPD Induced by LPS and Cigarette Smoke
DOI: https://doi.org/10.2147/copd.s449521
2024-04-19
International Journal of COPD
Abstract:Liguo Lu, 1, 2 Chengdong Zhu, 3 Jian Xu, 4 Yulan Hu, 2 Juxiang Dai, 2 Sheng Wang, 2 Tao Wei 1, 5 1 Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogenic Biology and Immunology, Xuzhou Medical University, Xuzhou, People's Republic of China; 2 Department of Respiratory and Critical Care Medicine, Shuyang Hospital, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian, People's Republic of China; 3 Department of Traditional Chinese Medicine, Shuyang Hospital, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian, People's Republic of China; 4 Taian Maternal and Child Health Hospital, Tai An, Shandong, People's Republic of China; 5 Public Experimental Research Center, Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China Correspondence: Tao Wei, 209 Tongshan Road, Xuzhou City, Jiangsu Province, People's Republic of China, Tel +8613815303574, Email Introduction: The Lifei Decoction (LD) is a commonly utilized Chinese medicine for the treatment of sepsis and bronchial inflammation. However, its therapeutic potential in chronic obstructive pulmonary disease (COPD) remains unknown. Therefore, the objective of this study was to investigate the therapeutic efficacy and underlying mechanism of LD in a mouse model of COPD induced by cigarette smoke (CS) combined with lipopolysaccharide (LPS). Methods: Hematoxylin-eosin (H&E) staining was employed to observe the pathological alterations in lung tissue, while ELISA was utilized for the detection of levels of inflammatory factors in both lung tissue and bronchoalveolar lavage fluid (BALF). Additionally, Western blot analysis was conducted to assess the expression of p-NF-κB, GDF11, ZO-1, and Occludin-1 proteins. The changes in intestinal flora were evaluated using the viable bacteria count method. Results: The administration of LD demonstrates significant efficacy in mitigating pulmonary tissue damage in a murine model, while concurrently inhibiting the activation of the inflammatory pathway NF-κB to attenuate the levels of pro-inflammatory factors. Moreover, LD exhibits the capacity to enhance the expression of intestinal functional proteins ZO-1 and Occludin-1, thereby rectifying dysbiosis within the gut microbiota. Conclusion: The LD shows great promise as a potential treatment for COPD. Keywords: COPD, lifei decoction, inflammation, intestinal flora Chronic obstructive pulmonary disease (COPD) is one of the chronic respiratory disorders worldwide, with a global incidence rate of 11.7%, resulting in approximately 3.2 million deaths annually. 1 In China, it has emerged as the fourth leading cause of mortality, imposing a substantial economic burden on society. 2 This condition typically arises from prolonged exposure to toxic particles or gases, triggering abnormal inflammation in the airways or lungs and subsequently impairing alveolar function. 3 Within modern society, cigarette smoking (CS) stands out as a critical risk factor for COPD due to its inclusion of reactive oxygen and other chemical components that activate non-specific inflammatory responses, thereby exacerbating disease progression. 3 The prevalence of COPD in long-term heavy smokers has been discovered to reach as high 50%, and the mitigation of inflammation can control symptom management and impede disease progression. 1 Currently employed treatment options for COPD encompass cough expectorants, glucocorticoids, bronchodilators, among others. 4 However, their effectiveness remains limited or they may induce severe side effects. Consequently, there is an urgent need to discover safer and more efficacious anti-COPD medications. In addition to inflammation, recent studies have revealed a close association between an imbalance in intestinal flora and the occurrence of respiratory diseases, including asthma, COPD, and lung cancer. 5,6 It has been observed that the composition differs of gut microbiota between COPD patients and healthy individuals. 7 The fecal microbiota transplantation experiment further demonstrated that the dysbiosis of gut microbiota aggravated the symptoms of COPD in mice. 8 These findings strongly substantiate the pivotal role of gut microbiota in the advancement of COPD. The dysbiosis of intestinal microbiota can impair the integrity of the intestinal barrier, thereby increasing the permeability of the mucosal lining and allowing bacteria or their metabolites, such as lipopolysaccharide (LPS), to enter the systemic circulation. 9 The LPS can then modulate the inflammatory immune response in -Abstract Truncated-
respiratory system